Chorionic gonadotropin has luteinizing, follicle-stimulating, and gonadotropic effects, while luteinizing activity is higher than follicle-stimulating. The active ingredient of the drug is human chorionic gonadotropin( hCG), a gonadotropin produced by the placenta during pregnancy (excreted by the kidneys in unchanged form). The method of obtaining the substance for the drug is to extract it from the urine, followed by purification. hCG is necessary for women and men for the normal growth and maturation of gametes, as well as for the production of sex hormones.
The drug stimulates the development of the genitals and secondary sexual characteristics. In addition, it promotes ovulation and stimulates the synthesis of estrogen (estradiol) and progesterone in women, as well as stimulates spermatogenesis, the production of dihydrotestosterone and testosterone in men.
After intravenous administration, it is well absorbed. The half-life is 8 hours. The maximum concentration of hCG in the blood plasma is observed after 4-12 hours. The half-life of chorionic gonadotropin is approximately 29-30 hours, with daily use, accumulation of the drug may be observed. Chorionic gonadotropin is excreted by the kidneys. Approximately 10-20% of the administered dose is found unchanged in the urine, the main part is excreted as fragments of the β-chain.
Women maintaining the yellow body phase; amenorrhea, anovulatory dysfunction of the ovaries.
Men and boys: delayed puberty associated with insufficient gonadotropic function of the pituitary gland;
- hypogonadotropic hypogonadism; oligoasthenospermia, insufficient spermatogenesis, azoospermia;
- cryptorchidism not associated with anatomical obstruction;
- conducting a Leydig functional test to assess testicular function in hypogonadotropic hypogonadism before prescribing long-term stimulating therapy;
- conducting a differential diagnostic test for cryptorchidism / anorchidism in patients with hypogonadotropic hypogonadism.
In / m, immediately after dissolving in the supplied solvent. For women: to induce ovulation — 5000 or 10000 IU, to maintain the function of the corpus luteum-1500-5000 IU on 3-6-9 days after ovulation.
In boys and men: with cryptorchidism, boys 3-6 years old — 1500 IU 1 time per week for 3 weeks (if necessary-in combination with gonadotropin-releasing hormone); to accelerate puberty in boys-1500 IU 2-3 times a week for 3 months; with hypogonadotropic hypogonadism-1500-6000 IU 1 time per week
|Active ingredient, IU||1000, 1500|
|1 bottle, IU||1000, 1500|
|Bottles in the package, pcs||5|
|Manufacturer||FGYP Pianta endocrina di Mosca|
|Packing||Bottle 1000 IU, Bottle 1500 IU, Packing (5 bottles 1500 IU), Packing (5 bottles 1000 IU)|